| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | Empliciti fka HuLuc63 | |
| 3 | Generic Name | elotuzumab | |
| 4 | Indication | Multiple Myeloma | |
| 5 | Mechanism | CS1/SLAMF7 mab | |
| 6 | Economics | ABBV co-development, BMY solely responsible for commercial activities | |
| 7 | Clinical Trials | ||
| 8 | Phase III n=640 Revlimid+dex+-elotuzumab | ||
| 9 | Primary endpoint is PFS | ||
| 10 | |||
| 11 | Phase II "ELOQUENT-3" pom+dex+-elotuzumab n=113 3L+ lenalidomide-refractory | ||
| 12 | |||
| 13 | |||
| 14 | Phase II n=73 Revlimid+dex+elotuzumab 10mg or 20mg | ||
| 15 | 92% ORR in 10mg and 73% ORR in 20mg | ||
| 16 | All patients had previously failed 1-3 prior therapies. |